Resultats de la cerca - Evans, Marc

Letter from the Editor per Evans, Marc

Obtenir text complet Obtenir text complet Obtenir text complet

Living with Type 2 Diabetes: Patient Commentary in Response to the Paper ‘SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice’ per Evans, Marc

Obtenir text complet Obtenir text complet Obtenir text complet

Pioglitazone in Clinical Practice: Where Are We Now? per Govindan, Joytish, Evans, Marc

Obtenir text complet Obtenir text complet Obtenir text complet

Practical Approaches to Diabetes Care: An Introduction per Evans, Marc, Maisey, Abigail

Obtenir text complet Obtenir text complet Obtenir text complet

A Summary of 2018 and What Lies Ahead for Diabetes Therapy in 2019 per Evans, Marc, Ovalle, Fernando

Obtenir text complet Obtenir text complet Obtenir text complet

Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective per Brown, Dominique Xavier, Evans, Marc

Obtenir text complet Obtenir text complet Obtenir text complet

Modeling the relationship between wolf control and cattle depredation per Kompaniyets, Lyudmyla, Evans, Marc A.

Obtenir text complet Obtenir text complet Obtenir text complet

Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials per Williams, David M., Evans, Marc

Obtenir text complet Obtenir text complet Obtenir text complet

Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies per Williams, David M., Evans, Marc

Obtenir text complet Obtenir text complet Obtenir text complet

Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver? per Williams, David M., Evans, Marc

Obtenir text complet Obtenir text complet Obtenir text complet

Correction to: Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies per Williams, David M., Evans, Marc

Obtenir text complet Obtenir text complet Obtenir text complet

Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus per Evans, Marc, Chubb, Barrie, Gundgaard, Jens

Obtenir text complet Obtenir text complet Obtenir text complet

Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK per Evans, Marc, Achha, Sayeed, Neslusan, Cheryl

Obtenir text complet Obtenir text complet Obtenir text complet

Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin per Evans, Marc, Wilkinson, Mathew, Giannpolou, Angeliki

Obtenir text complet Obtenir text complet Obtenir text complet

Blood pressure and fasting lipid changes after 24 weeks’ treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitus per Evans, Marc, Schweizer, Anja, Foley, James E

Obtenir text complet Obtenir text complet Obtenir text complet

Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective per Evans, Marc, Gundgaard, Jens, Hansen, Brian Bekker

Obtenir text complet Obtenir text complet Obtenir text complet

What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer? per Evans, Marc, Morgan, Angharad R., Yousef, Zaheer

Obtenir text complet Obtenir text complet Obtenir text complet

Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials per Williams, David M., Nawaz, Asif, Evans, Marc

Obtenir text complet Obtenir text complet Obtenir text complet

Drug Therapy in Obesity: A Review of Current and Emerging Treatments per Williams, David M., Nawaz, Asif, Evans, Marc

Obtenir text complet Obtenir text complet Obtenir text complet

Diabetes and Novel Coronavirus Infection: Implications for Treatment per Williams, David M., Nawaz, Asif, Evans, Marc

Obtenir text complet Obtenir text complet Obtenir text complet